Vertex Pharmaceuticals Incorporated or Supernus Pharmaceuticals, Inc.: Who Leads in Yearly Revenue?

Vertex's Revenue Soars, Outpacing Supernus by 1,600% in a Decade

__timestampSupernus Pharmaceuticals, Inc.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 2014122045000580415000
Thursday, January 1, 20151444270001032336000
Friday, January 1, 20162150030001702177000
Sunday, January 1, 20173022380002488652000
Monday, January 1, 20184088970003047597000
Tuesday, January 1, 20193927550004162821000
Wednesday, January 1, 20205203970006205683000
Friday, January 1, 20215797750007574400000
Saturday, January 1, 20226672380008930700000
Sunday, January 1, 20236075210009869200000
Monday, January 1, 202411020100000
Loading chart...

In pursuit of knowledge

Vertex vs. Supernus: A Decade of Revenue Growth

In the competitive landscape of pharmaceuticals, Vertex Pharmaceuticals Incorporated and Supernus Pharmaceuticals, Inc. have shown distinct trajectories over the past decade. From 2014 to 2023, Vertex has consistently outpaced Supernus in annual revenue, showcasing a remarkable growth of over 1,600%. Starting with a revenue of approximately $580 million in 2014, Vertex reached nearly $9.9 billion by 2023. This growth underscores Vertex's strategic advancements in the biotech sector.

Conversely, Supernus, while experiencing a steady increase, grew its revenue by about 400% during the same period, from $122 million to over $600 million. This growth reflects Supernus's focus on niche markets and innovative therapies. The data highlights the dynamic nature of the pharmaceutical industry, where strategic focus and innovation drive financial success. As we look to the future, these trends offer insights into the evolving strategies of these industry players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025